Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones

• Accomplished CFO and COO with proven track record in the biotech and pharmaceutical industry
• Strengthens Curve’s Leadership Team following £40.5 million Series A financing

Southampton, UK, 9 July 2024 - Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets, today announces the appointment of Simon Jones as Chief Financial Officer (CFO) and Chief Operating Officer (COO).

Simon has over 20 years of experience in the biotech and pharma sector. He is an accomplished C-Suite executive with a skill set that includes senior operational and commercial roles within the life-science sector, including significant venture fundraising and deal-making. He joins from SpyBiotech, where he headed the Finance and Operations functions, during which time the Company successfully took its lead vaccine candidate into the clinic. This followed almost a decade as CFO at Karus Therapeutics where he managed the financial operations as the Company secured a sizeable funding round from US and EU investors, as well as investment through the UK Government’s Future Fund Scheme. Prior to this, Simon was CFO at various early-stage life sciences companies, including Eykona Technologies and Glide Pharmaceutical Technologies, which transitioned from development to commercialisation.

Simon Kerry, Chief Executive Officer of Curve Therapeutics, commented: “Simon brings extensive financial experience at the leadership level from multiple clinical stage biotech companies. His appointment comes at a pivotal time as we look to expand our team, advance our proprietary Microcycle® discovery platform, and progress our pipeline of potential first-in-class assets.”

Simon Jones, Chief Financial Officer and Chief Operating Officer of Curve Therapeutics, said: “Curve’s revolutionary Microcycle discovery platform and rich pipeline of assets means that it is a company primed to disrupt the drug discovery space. I am excited to be joining as the Company expands and transitions to become a clinical stage company.”

Curve Therapeutics’ mission is to unlock the therapeutic potential of complex and challenging disease targets that are intractable to conventional discovery methods. Through the utilisation of its world leading Microcycle discovery platform, Curve can screen directly inside mammalian cells, allowing for the identification of biologically active library members within an intracellular environment where both the library and the target are present in their native conformations. Curve is developing a small-molecule dual inhibitor of HIF-1 and HIF-2, along with an inhibitor of ATIC homodimerization, both with first-in-class potential.